UCB, INC.

Monitored H.R.2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024, as it relates to FDA funding. Monitored H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024, as it relates to FDA funding. Monitored H.R.4366, Consolidated Appropriations Act, 2024, as it relates to FDA funding and pharmacy benefit reforms. Monitored H.R. 2882, Further Consolidated Appropriations Act, 2024, as it relates to drug pricing.

Monitored implementation of P.L.117-169, the Inflation Reduction Act, as it relates to corporate and international taxes. Issues related to the Orphan Drug Tax Credit. H.R. 7024, Tax Relief for American Families and Workers Act of 2024, as it relates to the R&D tax credit. Monitored H.R. 3665, Defending American Jobs & Investment Act, as it relates to taxation of foreign-based multinationals.

Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act, and issues related to value-based payment arrangements. Issues related to Medicaid Drug Rebate Program. H.R. 5397, Joe Fiandra Access to Home Infusion Act of 2023. Issues concerning cybersecurity.

S. 652 / H.R. 2630, Safe Step Act and issues related to medication step therapy. Monitored issues related to pharmacy benefit management. S.1375 / H.R. 830, HELP Copays Act, as it relates to out-of-pocket costs for prescription drugs.